Scientific Resources
Your Ardelyx Medical Medical Science Liaison (MSL) is available for engaging in scientific exchange related to Ardelyx Medical products, disease states, and clinical practice trends.
Gastroenterology
Study Infographics
Scientific Posters
- Assessment of Diarrhea in IBS-C Patients (2023)
- Abdominal Symptoms Independent of CSBM (2023)
- Bloating and Overall CSBM Response (2023)
- Efficacy in Subgroups of Patients with IBS-C (2023)
- Quality of Life (2022)
- Early Onset of Action (2022)
- Treatment of Abdominal Symptoms (2022)
- Multi-item Abdominal Score (2022)
Nephrology
Study Infographics
Scientific Posters
- Patient Perception of Phosphate-Lowering Treatment Regimen Improves Adherence to Therapy (2024)
- Tenapanor Treatment Added to Phosphate Binders Improved Long-Term Serum Phosphate Control as Measured by Reduction in Average Daily Phosphate Area Under the Curve (2024)
- Treatment Response to Tenapanor Categorized by Age and Comorbidities: A Post Hoc Analysis of the PHREEDOM Study (2024)
- Addition of Tenapanor and Reduction of Phosphate Binders Improved Phosphate Control Similarly in Patients Undergoing Hemodialysis and Peritoneal Dialysis (2024)
- Tenapanor Reduces Serum Phosphate With Similar Efficacy and Tolerability Profiles When Added to Various Phosphate Binders (2024)
- Sustained Phosphate Reduction Assessed by Serum Phosphate Area Under the Curve With Tenapanor Is Associated With Reduced Fibroblast Growth Factor 23 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Dialysis (2024)
- Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis With Hyperphosphatemia (2023)
- Tenapanor in Combination With Phosphate Binders Improves Short and Long-term Control of Serum Phosphate (sP) in Patients on Dialysis With Hyperphosphatemia (2023)
- An In-Depth Analysis of Serum Phosphate Changes in Patients With CKD on Dialysis: Results From the PHREEDOM Study (2023)
- Post Hoc Analyses of Serum Phosphate Changes With Tenapanor in Black/ African American and White Patients on Maintenance Dialysis (2023)
- Patient Education Improves Adherence to Tenapanor Treatment in OPTIMIZE Study (2023)
- Post Hoc Analyses of Serum Phosphate Changes With Tenapanor in Black/African American and White Patients on Maintenance Dialysis (2023)
- Safety Analysis of Tenapanor Monotherapy vs Sevelamer Carbonate in Patients on Maintenance Dialysis With Hyperphosphatemia (2023)
- Tenapanor in Combination With Phosphate Binders Improves Short and Long-term Control of Serum Phosphate (sP) in Patients on Dialysis With Hyperphosphatemia (2023)
- Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Sub-Analysis of the OPTIMIZE Study (2023)
- An In-Depth Analysis of Serum Phosphate Changes in Patients With CKD on Dialysis: Results From the PHREEDOM Study (2023)
- Evaluation of Changes in Serum FGF23 With Tenapanor Treatment in Patients With Chronic Kidney Disease on Dialysis (2023)
- Reduction of Serum Phosphate With Tenapanor in Patients With Chronic Kidney Disease on Maintenance Dialysis With Severe Hyperphosphatemia (2022)
- Tenapanor Plus Phosphate Binder Reduces Interdialytic Weight Gain in Patients With Chronic Kidney Disease on Hemodialysis: Post Hoc Analysis of the AMPLIFY Study (2022)
- The True State of Hyperphosphatemia Management in Dialysis (2020)